Compare RUN & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RUN | RCUS |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.8B |
| IPO Year | 2015 | 2018 |
| Metric | RUN | RCUS |
|---|---|---|
| Price | $12.47 | $27.43 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 11 |
| Target Price | $18.80 | ★ $30.27 |
| AVG Volume (30 Days) | ★ 7.6M | 999.3K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 113.35 | N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | ★ $858,578,000.00 | $247,000,000.00 |
| Revenue This Year | $2.81 | N/A |
| Revenue Next Year | $4.54 | $45.62 |
| P/E Ratio | $6.87 | ★ N/A |
| Revenue Growth | ★ 12.97 | N/A |
| 52 Week Low | $5.38 | $7.06 |
| 52 Week High | $22.44 | $26.40 |
| Indicator | RUN | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 44.75 | 68.87 |
| Support Level | $12.01 | $19.62 |
| Resistance Level | $13.57 | N/A |
| Average True Range (ATR) | 0.69 | 1.56 |
| MACD | 0.01 | 0.38 |
| Stochastic Oscillator | 24.75 | 84.77 |
Sunrun is engaged in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems in the United States. The company acquires customers directly and through relationships with various solar and strategic partners. The solar systems are constructed by Sunrun or by Sunrun's partners and are owned by the company. Sunrun's customers typically enter into 20- to 25-year agreements to utilize its solar energy system. The company also sells solar energy systems and products, such as panels and racking, and solar leads generated to customers.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.